Researchers plumbing mysterious RNAs find a possible treatment
WWhen hundreds of scientists from around the world finally pieced together a draft of the first human genome in 2003, perhaps the biggest surprise was how little of it was devoted to producing proteins. About 98% of the genes in our chromosomes seemed to do nothing, earning the unflattering nickname “junk DNA.” But with better tools developed over the past 20 years, scientists began to discover that all that junk actually produces a diverse menagerie of RNA species that are transcribed and released to float through the cell.
Figuring out exactly what everyone is doing is the mission of an increasing number of researchers, including a team from the MD Anderson Cancer Center in Texas. Years ago, they wanted to determine the functions of one RNA species in particular — large ones, larger than 200 bases, known as long noncoding RNAs or lncRNAs. Now they’ve linked one of these RNA molecules to a discovery they believe could help develop new treatments for one of the most common genetic disorders, phenylketonuria.
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific breakthroughs and clinical research findings, and healthcare disruption in Silicon Valley and beyond.
What’s in it?
- Daily reporting and analysis
- The industry’s most comprehensive coverage from a powerful team of reporters
- Newsletters only for subscribers
- Daily newsletters to inform you about the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to connect with our reporters and industry leading experts in live video calls
- Exclusive Industry Events
- Premium access to network events for subscribers across the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in healthcare
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.
Comments are closed.